There was little to expect from this 1H set of results and they are mostly in line with our estimates. Cash was in line as well at €105m, but should come down in 2H, so the cash position will be restored again to pay the bullet loan maturing in May 2027. We expect a share buyback to follow but, in the meantime, KBC Ancora may still decide to lower the 10% that is reserved: if this is lowered to 0%, it would add c.€8 per share on our new target price of €91.0 (previously €85.0). We reiterate our ...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...
Friday during trading hours, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of pediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. Following the positive CHMP opinion...
Interim Financial Report 2025/2026 Regulated information, Leuven, 30 January 2026 (17.40 hrs CET) Interim Financial Report 2025/2026 KBC Ancora recorded a profit of EUR 74.4 million in the first half of the financial year 2025/2026. This compared with a profit of EUR 73.9 million in the same period in the previous financial year. The result for the first six months of the financial year was determined chiefly by dividend income totalling EUR 77.5 million from the participating interest in KBC Group, operating costs of EUR 1.5 million and interest charges amounting to EUR 2.0 million. Abr...
Halfjaarlijks financieel verslag 2025/2026 Gereglementeerde informatie, Leuven, 30 januari 2026 (17.40 CET) Halfjaarlijks financieel verslag 2025/2026 In de eerste helft van boekjaar 2025/2026 boekte KBC Ancora een winst van 74,4 miljoen euro, tegenover een winst van 73,9 miljoen euro over dezelfde periode in het vorige boekjaar. De eerste zes maanden van het boekjaar werden in hoofdzaak gekenmerkt door 77,5 miljoen euro aan dividendopbrengsten uit de participatie in KBC Groep, 1,5 miljoen euro operationele werkingskosten en 2,0 miljoen euro aan interestlasten. Verkorte financiële overzi...
Rapport financier semestriel 2025/2026 Informations réglementées, Leuven, 30 janvier 2026 (17.40 CET) Rapport financier semestriel 2025/2026 Au cours de la première moitié de l’exercice 2025/2026, KBC Ancora a affiché un bénéfice de 74,4 millions d’euros, contre un bénéfice de 73,9 millions d’euros pour la même période de l’exercice précédent. Les six premiers mois de l’exercice se sont principalement caractérisés par 77,5 millions d’euros de produits de dividendes provenant de la participation dans KBC Groupe, 1,5 million d’euros de charges opérationnelles et 2,0 millions d’euros de char...
Ahold Delhaize: Conditional approval for the acquisition of Delfood / Bekaert: Acquires Bridgestone's €80m tyre cord business in China and Thailand / KPN: In-line Q4, 2026 guidance, cash returns / NSI: Results in line, further vacancy weighing on 2026 and cautious tone on new developments / UCB: Cimzia included in Medicare's price negotiations for 2028
Aedifica and Cofinimmo: Belgian Competition Authority approves the deal / AEGON: Sale of UK picking up early momentum / Allfunds Group PLC: Of Bourse they agreed / Ontex: Peer Essity 4Q25 results / Telecoms: Digital Networks Act take-aways / WDP: Catena to raise c.€255m via an ABB with WDP participating pro-rata for c.€26m
We reiterate our BUY rating and raise our target price from €257 to €310. UCB finished the year strongly, after upgrading its guidance for a second time in FY25. This upgraded guidance was mainly driven by an exceptional performance for Bimzelx, the group's key growth engine and which continues to surprise to the upside. This gives us comfort into our peak sales of €8.5bn for Bimzelx by 2032F, especially as the performance of Bimzelx in Hidradenitis Suppurativa remains strong. Alongside Bimzelx,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.